An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will provide treatment with erlotinib to participants with advanced NSCLC who have
received at least one course of standard chemotherapy or radiation therapy, or who are not
medically suitable for either. Efficacy and safety will be monitored throughout the study.